ASP ISOTOPES INC - ASP Isotopes Inc. announces that Renergen Limiteds Virginia Gas Project has achieved stable liquid helium production

ASP Isotopes Inc. announces that Renergen Limited’s Virginia Gas Project has achieved stable liquid helium production

ASP ISOTOPES INC.
(Incorporated in the State of Delaware,
United States of America)
(Delaware file number 6228898)
Ticker Symbol: NASDAQ: ASPI
ISIN: US00218A1051
LEI: 6488WHV94BZ496OZ3219
JSE Share Code: ISO


ASP ISOTOPES INC. ANNOUNCES THAT RENERGEN LIMITED’S VIRGINIA GAS PROJECT HAS ACHIEVED STABLE LIQUID HELIUM PRODUCTION

Phase 1 plant now in stable operation following commissioning; first liquid helium in storage
ahead of initial deliveries to contracted offtakers

DALLAS, October 26, 2026 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ: ASPI) (“ASP
Isotopes” or the “Company”), an advanced materials company focused on developing technologies and
processes for the production of critical materials used in multiple industries, today announced that
Tetra4 Proprietary Limited (“Tetra4”), a subsidiary of Renergen Limited (“Renergen”), has completed
commissioning and achieved stable production of liquid helium. Liquid helium is now accumulating in
Tetra4’s cryogenic storage ahead of initial deliveries under existing offtake agreements. The Virginia
Gas Project holds South Africa’s first onshore petroleum production right and is the country’s first
integrated producer of both liquid helium and liquefied natural gas (“LNG”).

“Stable helium production at the Virginia Gas Project is a defining milestone for Renergen and for ASP
Isotopes” said Paul Mann, Executive Chairman and Chief Executive Officer of ASP Isotopes, and Chief
Executive Officer of Renergen. “With global helium supply under significant pressure, a new,
independent source matters more than ever, and our offtake partners have been waiting for exactly this.
We are now ramping towards nameplate capacity, which we expect to reach during the fourth quarter
of 2026, and we are finalising logistics with our offtakers for first deliveries.”

Phase 1 is expected to produce approximately 2,500 GJ/day of LNG and approximately 70 Mcf/day of
liquid helium.

About ASP Isotopes Inc.

ASP Isotopes Inc. is an advanced materials company focused on developing technologies and
processes for the production of critical materials used in multiple industries, including nuclear medicine,
electronics and nuclear energy. The Company's proprietary Aerodynamic Separation Process ("ASP
technology") and Quantum Enrichment ("QE technology") are designed to enable the production of
isotopes for a range of industrial and advanced technology applications. The Company operates isotope
enrichment facilities in Pretoria, South Africa, focused on low atomic mass elements, or light isotopes,
and a gas production facility in Free State Province, South Africa, focused on liquid natural gas and
liquid helium. For more information, please visit www.aspisotopes.com.

About Renergen

Renergen Limited, a subsidiary of ASP Isotopes Inc., is a company incorporated under the laws of the
Republic of South Africa whose principal asset is its 94.5% equity interest in Tetra4 Proprietary Limited,
which owns an onshore petroleum production right and is engaged in the exploration and production of
natural gas and the processing of natural gas into liquid natural gas and liquid helium in Free State
Province, South Africa.

Important Additional Information and Where to Find It

This press release relates to the proposed merger and related transactions (the “Proposed
Transactions”) involving ENDRA Life Sciences Inc. (“ENDRA”), ASP Isotopes, Renergen and Noble
Africa LLC, a subsidiary of ASP Isotopes and future holding company for Renergen (“Noble Africa”),
and may be deemed to be solicitation material in respect of the Proposed Transactions. In connection
with the Proposed Transactions, ENDRA has filed relevant materials with the SEC, including a
registration statement on Form S-4 (the “Form S-4”) that contains a proxy statement (the “Proxy
Statement”) and prospectus. This press release is not a substitute for the Form S-4, the Proxy
Statement or for any other document that ENDRA may file with the SEC and/or send to its stockholders
in connection with the Proposed Transactions. INVESTORS AND STOCKHOLDERS OF ENDRA ARE
URGED TO READ THE FORM S-4, THE PROXY STATEMENT AND ANY OTHER RELEVANT
DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR
SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN
THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT
ENDRA, ASP ISOTOPES, RENERGEN, NOBLE AFRICA, THE PROPOSED TRANSACTIONS AND
RELATED MATTERS.

Investors and stockholders will be able to obtain free copies of the Form S-4, the Proxy Statement and
other documents filed by ENDRA and ASP Isotopes with the SEC (when they become available)
through the website maintained by the SEC at www.sec.gov. ENDRA’S Internet website address is
www.endrainc.com. ENDRA’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current
Reports on Form 8-K, including exhibits, and amendments to those reports filed or furnished pursuant
to Section 13(a) or 15(d) of the Exchange Act are available free of charge through the investor relations
page of its Internet website as soon as reasonably practicable after it electronically files such material
with, or furnishes such material to, the SEC.

Participants in the Solicitation

ENDRA, ASP Isotopes, Renergen, Noble Africa, and their respective directors and managers and
certain of their executive officers and other members of management may be deemed to be participants
in the solicitation of proxies from ENDRA’s stockholders in connection with the Proposed Transactions
under the rules of the SEC. Information about ENDRA’s directors and executive officers, including a
description of their interests in ENDRA, is included in ENDRA’s most recent Annual Report on Form
10-K for the year ended December 31, 2025. Information about ASP Isotopes’ directors and executive
officers, including a description of their interests in ASP Isotopes, is included in ASP Isotopes’ most
recent Annual Report on Form 10-K for the year ended December 31, 2025. Additional information
regarding the persons who may be deemed participants in the proxy solicitations, including the directors
and executive officers of Renergen, and a description of their direct and indirect interests, by security
holdings or otherwise, are also included in the Form S-4 and the Proxy Statement and may be included
in other relevant materials filed with the SEC. These documents can be obtained free of charge from
the sources indicated above.

No Offer or Solicitation

This press release is not intended to and does not constitute a solicitation of a proxy, consent or
approval with respect to any securities or in respect of the Proposed Transactions or an offer to sell or
the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any
securities pursuant to the Proposed Transactions or otherwise, nor shall there be any sale, issuance or
transfer of securities in any jurisdiction in contravention of applicable law. No offering of securities shall
be made except by means of a prospectus meeting the requirements of Section 10 of the Securities
Act of 1933, as amended, and otherwise in accordance with applicable law, or an exemption therefrom.
Subject to certain exceptions to be approved by the relevant regulators or certain facts to be
ascertained, the public offer will not be made directly or indirectly, in or into any jurisdiction where to do
so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means
or instrumentality (including without limitation, facsimile transmission, telephone and the internet) of
interstate or foreign commerce, or any facility of a national securities exchange, of any such jurisdiction.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are
neither historical facts nor assurances of future performance. Instead, they are based only on our
current beliefs, expectations, and assumptions regarding the future of our business, future plans and
strategies, projections, anticipated events and trends, the economy, and other future conditions.
Forward-looking statements can be identified by words such as “anticipates,” “believes,” “could,”
“estimates,” “expects,” “intends,” “may,” “might,” “plans,” “projects,” “will,” and words of a similar nature.
Examples of forward-looking statements include, but are not limited to, statements relating to the
expected production quantities of LNG and liquid helium, Renergen’s expected revenues, the Proposed
Transactions; the expected structure, timing and the completion of the Proposed Merger, the Proposed
Transactions and the expected effects, perceived benefits or opportunities of the Proposed
Transactions; the combined company’s listing on Nasdaq after the closing of the Proposed
Transactions; expectations regarding the structure, timing and completion of the Proposed
Transactions, including investment amounts from investors, timing of closing of the Proposed
Transactions, expected proceeds, expectations regarding the use of proceeds, and impact on
ownership structure; the anticipated timing of the closing of the Proposed Transaction; the expected
executive officers and directors of the combined company; each company’s and the combined
company’s expected cash position at the closing of the Proposed Transactions and cash runway of the
combined company following the Proposed Transactions; the future operations and pipeline, estimates
of financial position, competitive landscape, addressable market and strategic and financial initiatives
of the combined company; the nature, strategy and focus of the combined company; statements
regarding the continuation of Renergen’s Virginia Gas Project and its funding timeline and other
statements that are not historical fact.

Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks,
and changes in circumstances that are difficult to predict, many of which are outside our control. Actual
results, financial condition, and events may differ materially from those indicated in the forward-looking
statements based upon a number of factors. Forward-looking statements are not a guarantee of future
performance or developments. You are strongly cautioned that reliance on any forward-looking
statements involves known and unknown risks and uncertainties. Therefore, you should not rely on any
of these forward-looking statements. There are many important factors that could cause actual results
and financial condition to differ materially from those indicated in the forward-looking statements,
including, but not limited to: the outcomes of various strategies and projects undertaken by Renergen;
the potential impact of laws or government regulations or policies in South Africa or elsewhere;
Renergen’s future capital requirements and sources and uses of cash; Renergen’s ability to obtain
funding for its operations and future growth, including debt funding for Phase 2 of the Virginia Gas
Project; Renergen’s reliance on the efforts of third parties; Renergen’s ability to complete Phase 1 and
2 of the Virginia Gas Project; the financial terms of any current and future commercial arrangements;
Renergen’s ability to complete certain transactions and realize anticipated benefits from acquisitions
and contracts; Renergen’s ability to comply with the terms of the loan and credit facilities of Renergen's
subsidiary Tetra4; the ability of Renergen and its subsidiaries to retain and hire key personnel; the
volatility of LNG and liquid helium prices; Renergen's success in discovering, estimating and developing
natural gas and helium reserves; actions of competitors or regulators; limitations in the availability of,
and costs of, supplies, materials, contractors and services that may delay the drilling or completion of
wells or make such wells more expensive; the amount and timing of future development costs;
uncertainties inherent in estimating quantities of natural gas and helium reserves and projecting future
rates of production and timing of development activities; risks relating to the lack of capital available on
acceptable terms to finance the Renergen's continued growth; the competitive nature of Renergen’s
industry; the risk that the conditions to the closing or consummation of the Proposed Transactions are
not satisfied, including the failure to timely obtain approval of the Proposed Merger from ENDRA
stockholders, if at all; the risk that the proposed financings are not completed in a timely manner, if at
all; uncertainties as to the timing of the consummation of the Proposed Transactions and the ability of
each of ENDRA and Noble Africa to consummate the Proposed Transactions; risks related to ENDRA’s
continued listing on Nasdaq until closing of the Proposed Transactions and the combined company’s
ability to remain listed following the closing of the Proposed Transactions; the ability to obtain debt
financing on terms that are favorable, or at all; the risk that Renergen does not receive funding from the
U.S. DFC or Standard Bank SA or that such funding is delayed; risks related to ENDRA’s ability to
correctly estimate its respective operating expenses and its respective expenses associated with the
Proposed Transactions, as applicable, pending the closing of the Proposed Transactions, as well as
uncertainties regarding the impact any delay in the closing would have on the anticipated cash
resources of ENDRA, and other events and unanticipated spending and costs that could reduce
ENDRA’s cash resources; risks related to the failure or delay in obtaining required approvals from any
governmental or quasi-governmental entity necessary to consummate the Proposed Transactions; the
occurrence of any event, change or other circumstance or condition that could give rise to the
termination of the merger agreement; the effect of the announcement or pendency of the Proposed
Merger on ENDRA’s or Renergen’s business relationships, operating results and business generally;
costs related to the Proposed Merger; risks related to the market price of ENDRA’s common stock
relative to the value suggested by the Proposed Merger; the outcome of any legal proceedings that may
be instituted against ENDRA, Noble or any of their respective directors, managers, or officers related
to the Proposed Transactions; costs of the Proposed Transactions and unexpected costs, charges or
expenses resulting from the Proposed Transactions; changes in regulatory requirements and
government incentives; risks associated with the possible failure to realize, or that it may take longer to
realize than expected, certain anticipated benefits of the Proposed Transactions, including with respect
to future financial and operating results, legislative, regulatory, political and economic developments,
and those uncertainties and factors; and the risk of involvement in litigation, including securities class
action litigation, that could divert the attention of the management of ENDRA or the combined company,
harm the combined company’s business and may not be sufficient for insurance coverage to cover all
costs and damages, and the other risks and uncertainties described in ENDRA’s SEC reports, and
under the heading “Risk Factors” in its most recent Annual Report on Form 10-K and Quarterly Reports
on Form 10-Q, the factors disclosed in Part I, Item 1A. “Risk Factors” of ASP Isotopes’ Annual Report
on Form 10-K for the fiscal year ended December 31, 2025 (as amended) and in ASP Isotopes’
subsequent reports filed with the SEC, each of which are available at www.sec.gov, and in other filings
that ENDRA and ASP Isotopes have made and will make with the SEC in connection with the Proposed
Transactions, including the Form S-4 and Proxy Statement described above under “Additional
Information and Where to Find It”. Any forward-looking statement made by the parties in this press
release is based only on information currently available to the parties and speaks only as of the date
on which it is made. The parties undertake no obligation to publicly update any forward-looking
statement, whether as a result of new information, future developments or otherwise. No information in
this press release should be interpreted as an indication of future success, revenues, results of
operations, or stock price. All forward-looking statements herein are qualified by reference to the
cautionary statements set forth herein and should not be relied upon.

Contact

IR@ASPIsotopes.com


The Company has a primary listing on the Nasdaq and a secondary listing on the Main Board of the
JSE.

26 October 2026

Sponsor
Valeo Capital Proprietary Limited
Date: 26/10/2026 02:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.